

IDYLLA™ FIRST

Guiding First-Line Therapy Decisions in NSCLC



FAST
ACTIONABLE

ACCURATE




IDYLLA™ FIRST
BECAUSE TIME MATTERS

Availability of biomarker results prior to first-line therapy is key to enhance patient outcomes

Although lung cancer remains the leading cause of cancer deaths worldwide, the survival rate has increased over the past few years due to the rapidly evolving treatment landscape for Non-Small Cell Lung Cancer (NSCLC).

Since **new therapies are becoming increasingly biomarker-driven**, an urgent and growing need for biomarker testing has emerged. **Molecular testing therefore plays a key role in the diagnostic work-up for early and late-stage NSCLC patients to guide therapy decisions in neo-adjuvant, adjuvant and metastatic settings.**

The accurate & fast diagnosis of these actionable biomarkers is critical for the right targeted therapy. Consequently, international treatment guidelines (ESMO, NCCN) recommend molecular testing for *EGFR*, *BRAF*, *ALK*, *ROS1*, *RET*, *MET*, *RET*, *MET*, *NTRK*, *HER2* and *KRAS G12C* in every patient diagnosed with advanced/metastatic NSCLC.




Time is of the essence in NSCLC


Today, the adoption rate of biomarker testing is far from ideal, resulting in suboptimal therapy decisions for many patients. One of the identified causes is the long turnaround time to receive biomarker results, in contrast with the critical need to start therapy immediately.

It has been demonstrated that **patients, for whom biomarker results were available prior to 1L therapy, have a better overall survival** as compared to patients for whom biomarker results were not available.

Overall Survival by Availability of Molecular Genotyping Results Prior to 1L Therapy²



>90% of patients with first-line actionable biomarkers can start the right targeted therapy immediately³




Idylla™ is a fully automated, easy to implement molecular testing platform suitable for any hospital lab setting and enabling **rapid in-house biomarker testing.**

Why IDYLLA™ FIRST?

- **Idylla™ helps save lives.** Patients die, rapidly deteriorate or receive sub-optimal treatment while waiting for their biomarker test results.⁵⁻⁷
- **Idylla™ alleviates patient anxiety** and allows them to focus on their well-being.^{8,9}
- **Idylla™ right first time.** Idylla™ shows low failure rates combined with the ability to produce accurate results.^{4,10,11}
- **Idylla™ only requires small sample sizes.** An NGS workflow needs nearly five times more tissue to meet NSCLC biomarker testing requirements.⁵

Idylla™ - A technology you can rely on

- **Strong scientific evidence** of Idylla™ in NSCLC in >50 publications
- Idylla™ shows **low failure rate** ($\leq 1.5\%$)^{4,10,11}
- **Proven** Idylla™ performance^{4,11}



Retrospective Study - Memorial Sloan Kettering Cancer Center, NY (US) - Standard of care: NGS¹¹

Prospective Study - 16 centers - Charité Berlin (DE) Standard of care: NGS - RT-PCR - Sanger⁴

Idylla™ - Actionable biomarker testing within 3 hours

Idylla™ solid biopsy assays focus on clinically relevant biomarkers according to **international clinical guidelines** of ASCO, ESMO, NCCN and IASLC

EGFR (IVD)	exons 18 - 21
GeneFusion (IVD)	ALK, ROS1, RET, METex14

Renowned institutions already implemented IDYLLA™ FIRST



Idylla™ meets the need for assessing EGFR on surgical specimens and enables better and rapid decision-making.

Prof. Dr. Nicolas Girard, Oncology Pneumology, Institut Curie, France



Our experience is fantastic. Idylla™ allows us to have an ultra-fast and reliable panel of biomarkers useful in therapeutic decision-making for the main molecular targets in lung cancer.

Dr. Antonio Calles, Medical Oncologist and KOL in lung cancer, Hospital Universitario Gregorio Marañón, Spain

REFERENCES

- (1) Kerr et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer. Apr 2021
- (2) Aggarwal et al. Presented at ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9022
- (3) Hendriks et al. on behalf of the ESMO Guidelines Committee. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023.
- (4) Behnke et al. FACILITATE A real-world multicenter prospective investigating the utility of fully automated real-time PCR assay versus local reference methods for detecting EGFR variants in NSCLC. Pathology & Oncology Research. Feb 2023
- (5) Finall et al. Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up. J Clin Path. Jan 2022
- (6) Hardstock et al. Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis. BMC Cancer. Mar 2020
- (7) Sadik et al. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer. JCO Precision Oncology. Oct 2022
- (8) Wheeldon et al. Use of the Biocartis Idylla™ Platform for the Detection of Epidermal Growth Factor Receptor, BRAF and KRAS Proto-Oncogene Mutations in Liquid-Based Cytology Specimens from Patients with Non-Small Cell Lung Carcinoma and Pancreatic Adenocarcinoma. J Mol Pathology. May 2022
- (9) Gregg et al. Molecular testing strategies in non-small cell lung cancer: Optimizing the diagnostic journey. Transl Lung Cancer Res. Jun 2019
- (10) Arcila et al. Ultra-Rapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens with a High Success Rate. JTO Clinical and Research Reports. Jul 2020
- (11) Chu et al. Clinical utility and performance of an ultra-rapid multiplex RNA-based assay for detection of ALK, ROS1, RET and NTRK1/2/3 rearrangements and MET exon 14 skipping alterations. J Mol Diag. Apr 2022

Biocartis NV
Generaal De Wittelaan 11B
2800 Mechelen - Belgium
+32 15 632 888
www.biocartis.com
customerservice@biocartis.com

Follow us on   

Idylla™ Platform, Idylla™ EGFR Mutation Test and Idylla™ GeneFusion Panel are available as IVDs in Europe and many other countries outside the US.

Biocartis and Idylla™ are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla™ trademarks and logos are used trademarks owned by Biocartis.

Idylla™ is available for sale in Europe, the US and many other countries. Please check availability with a Biocartis representative.

© July 2023, Biocartis NV. All rights reserved.

